Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase 2 multicentre, open-label feasibility trial

CONCLUSION: Efgartigimod was well-tolerated and exhibited an early effect on disease activity and outcome parameters, providing support for further evaluation as a therapy for pemphigus. The study is registered at ClinicalTrials.gov (identifier: NCT03334058).PMID:34608631 | DOI:10.1111/bjd.20782

Source: The British Journal of Dermatology - October 5, 2021 Category: Dermatology Authors: M Goebeler Z Bata-Cs örgő C De Simone B Didona E Remenyik N Reznichenko J Stoevesandt E S Ward W Parys H de Haard P Dupuy P Verheesen E Schmidt P Joly ARGX-113-1701 Investigator Study Group Source Type: research